Vaginal estriol-lactobacilli combination (Gynoflor(®)) therapy and sexual quality of life in aromatase inhibitor-treated breast cancer patients with atrophic vaginitis
Buchholz, S × Mögele, M Lintermans, A Bellen, G Prasauskas, V Ortmann, O Grob, P Neven, Patrick Donders, G #
Climacteric vol:18 issue:2 pages:252-259
ABSTRACT Objective: We investigated the effect of a combination of vaginal ultra-low-dose estriol with lactobacilli on the sexual functioning domain of quality of life (QOL) during the treatment of breast cancer (BC) survivors on an aromatase inhibitor (AI) with vaginal atrophy. Subjects and Methods: This was an open label bicentric exploratory clinical study, in 16 postmenopausal BC survivors on AI suffering from vaginal atrophy-induced sexual disorders. Atrophy symptoms were assessed by scoring with an 11-point estimation scale (0 = not at all, 10 = worst imaginable feeling). Sexuality parameters of QOL and medication adherence were recorded in patient's diary and in 'Female Somatic Sexual Experience Instrument (FSSEI) questionnaire. Patients underwent an initial treatment for 4 weeks (1 vaginal tablet of Gynoflor(®) containing 0.03 mg estriol daily), followed by maintenance therapy (3 vaginal Gynoflor(®) tablets weekly) for 8 weeks. Results: Vaginal dryness continuously improved from a median score 8 at entry to score 4 at the end of initial therapy, and median score 2 at the end of maintenance therapy. Normal sexual activity before BC diagnosis was reported by 14 women (88%). At study entry only 3 women (19 %) were sexually active. At the end of the Gynoflor(®) regimen, 10 women (63%) reported sexual activity, of which 7 (44%) sexual intercourse. The FSSEI demonstrated a non-significant trend of improvement of parameters related to sexuality Conclusions: Local vaginal therapy with Gynoflor(®) in BC survivors on AIs reporting atrophic vaginitis could be considered as a useful treatment the quality of the sexual life.